Particle.news
Download on the App Store
3 ARTICLES
·
last wk.

Pfizer Licenses Novavax’s Matrix‑M for Up to Two Vaccine Areas in Deal Worth Up to $530 Million

The arrangement advances Novavax’s partnership strategy by broadening access to its adjuvant as Pfizer assumes development and commercialization.

Pfizer and Novavax have forged a deal worth up to $530m, with Novavax's Matrix-M adjuvant at the centre of it. Image credit: Kmpzzz via ShutterStock.com.
Image

Overview

  • Novavax received $30 million upfront and is eligible for up to $500 million in development and sales milestones, plus tiered high mid‑single‑digit royalties on any Pfizer products using Matrix‑M.
  • The license is non‑exclusive and covers use of Matrix‑M with Pfizer’s products in up to two disease areas.
  • Pfizer will lead development and commercialization of any Matrix‑M–containing products, while Novavax will supply the adjuvant.
  • The companies did not disclose which disease areas Pfizer will target under the agreement.
  • Novavax cautioned that milestone and royalty outcomes depend on clinical progress, regulatory approvals, technology transfer, and manufacturing readiness.